Research programme: eye disorder therapeutics - MacuCLEAR
Alternative Names: MC-4001Latest Information Update: 16 Jul 2016
At a glance
- Originator MacuCLEAR
- Class
- Mechanism of Action Interleukin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA